CN103876157B - Soyasterol tablet with health care function and preparation method of soyasterol tablet - Google Patents
Soyasterol tablet with health care function and preparation method of soyasterol tablet Download PDFInfo
- Publication number
- CN103876157B CN103876157B CN201410147169.XA CN201410147169A CN103876157B CN 103876157 B CN103876157 B CN 103876157B CN 201410147169 A CN201410147169 A CN 201410147169A CN 103876157 B CN103876157 B CN 103876157B
- Authority
- CN
- China
- Prior art keywords
- tablet
- sojasterol
- soyasterol
- percent
- health care
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- 230000036541 health Effects 0.000 title claims abstract description 23
- 238000002360 preparation method Methods 0.000 title claims abstract description 14
- 239000000843 powder Substances 0.000 claims abstract description 32
- 239000000463 material Substances 0.000 claims abstract description 28
- TZCPCKNHXULUIY-RGULYWFUSA-N 1,2-distearoyl-sn-glycero-3-phosphoserine Chemical compound CCCCCCCCCCCCCCCCCC(=O)OC[C@H](COP(O)(=O)OC[C@H](N)C(O)=O)OC(=O)CCCCCCCCCCCCCCCCC TZCPCKNHXULUIY-RGULYWFUSA-N 0.000 claims abstract description 19
- ZWZWYGMENQVNFU-UHFFFAOYSA-N Glycerophosphorylserin Natural products OC(=O)C(N)COP(O)(=O)OCC(O)CO ZWZWYGMENQVNFU-UHFFFAOYSA-N 0.000 claims abstract description 19
- 235000007688 Lycopersicon esculentum Nutrition 0.000 claims abstract description 16
- 239000000203 mixture Substances 0.000 claims abstract description 9
- 150000002148 esters Chemical class 0.000 claims description 23
- 150000002168 ethanoic acid esters Chemical class 0.000 claims description 16
- 239000000126 substance Substances 0.000 claims description 6
- 241000227653 Lycopersicon Species 0.000 claims 5
- 238000000034 method Methods 0.000 claims 1
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 abstract description 19
- 240000003768 Solanum lycopersicum Species 0.000 abstract description 11
- 235000012000 cholesterol Nutrition 0.000 abstract description 8
- 210000004369 blood Anatomy 0.000 abstract description 7
- 239000008280 blood Substances 0.000 abstract description 7
- 230000006870 function Effects 0.000 abstract description 6
- 206010028980 Neoplasm Diseases 0.000 abstract description 5
- 230000036772 blood pressure Effects 0.000 abstract description 4
- 201000010099 disease Diseases 0.000 abstract description 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract description 4
- 210000002307 prostate Anatomy 0.000 abstract description 4
- 206010061218 Inflammation Diseases 0.000 abstract description 2
- 235000019197 fats Nutrition 0.000 abstract description 2
- 230000004054 inflammatory process Effects 0.000 abstract description 2
- 238000004519 manufacturing process Methods 0.000 abstract description 2
- MBMBGCFOFBJSGT-KUBAVDMBSA-N all-cis-docosa-4,7,10,13,16,19-hexaenoic acid Chemical compound CC\C=C/C\C=C/C\C=C/C\C=C/C\C=C/C\C=C/CCC(O)=O MBMBGCFOFBJSGT-KUBAVDMBSA-N 0.000 abstract 4
- 229940090949 docosahexaenoic acid Drugs 0.000 abstract 2
- 235000020669 docosahexaenoic acid Nutrition 0.000 abstract 2
- 239000000047 product Substances 0.000 abstract 2
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 abstract 1
- 240000008397 Ganoderma lucidum Species 0.000 abstract 1
- 235000001637 Ganoderma lucidum Nutrition 0.000 abstract 1
- 239000013067 intermediate product Substances 0.000 abstract 1
- 229940092309 pumpkin seed extract Drugs 0.000 abstract 1
- 238000005303 weighing Methods 0.000 abstract 1
- 238000012360 testing method Methods 0.000 description 13
- 230000000694 effects Effects 0.000 description 11
- 206010039966 Senile dementia Diseases 0.000 description 4
- 150000002632 lipids Chemical class 0.000 description 4
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- 208000024827 Alzheimer disease Diseases 0.000 description 3
- 208000024172 Cardiovascular disease Diseases 0.000 description 3
- 201000011510 cancer Diseases 0.000 description 3
- 235000013305 food Nutrition 0.000 description 3
- 230000002265 prevention Effects 0.000 description 3
- UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 description 3
- 208000007530 Essential hypertension Diseases 0.000 description 2
- 108010023302 HDL Cholesterol Proteins 0.000 description 2
- 241000408747 Lepomis gibbosus Species 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- 208000025844 Prostatic disease Diseases 0.000 description 2
- 229930182558 Sterol Natural products 0.000 description 2
- 230000001093 anti-cancer Effects 0.000 description 2
- 230000003110 anti-inflammatory effect Effects 0.000 description 2
- 210000004556 brain Anatomy 0.000 description 2
- 210000004958 brain cell Anatomy 0.000 description 2
- 208000026106 cerebrovascular disease Diseases 0.000 description 2
- 230000002526 effect on cardiovascular system Effects 0.000 description 2
- 230000003203 everyday effect Effects 0.000 description 2
- 210000004185 liver Anatomy 0.000 description 2
- 235000020236 pumpkin seed Nutrition 0.000 description 2
- 230000009467 reduction Effects 0.000 description 2
- 210000002966 serum Anatomy 0.000 description 2
- 210000000952 spleen Anatomy 0.000 description 2
- -1 sterol ester Chemical class 0.000 description 2
- 235000003702 sterols Nutrition 0.000 description 2
- 210000002784 stomach Anatomy 0.000 description 2
- YUFFSWGQGVEMMI-JLNKQSITSA-N (7Z,10Z,13Z,16Z,19Z)-docosapentaenoic acid Chemical compound CC\C=C/C\C=C/C\C=C/C\C=C/C\C=C/CCCCCC(O)=O YUFFSWGQGVEMMI-JLNKQSITSA-N 0.000 description 1
- 206010004446 Benign prostatic hyperplasia Diseases 0.000 description 1
- 206010006187 Breast cancer Diseases 0.000 description 1
- 208000026310 Breast neoplasm Diseases 0.000 description 1
- 206010011224 Cough Diseases 0.000 description 1
- 235000021294 Docosapentaenoic acid Nutrition 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 208000008967 Enuresis Diseases 0.000 description 1
- 206010020772 Hypertension Diseases 0.000 description 1
- 206010020880 Hypertrophy Diseases 0.000 description 1
- 208000001953 Hypotension Diseases 0.000 description 1
- 206010058467 Lung neoplasm malignant Diseases 0.000 description 1
- UPYKUZBSLRQECL-UKMVMLAPSA-N Lycopene Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1C(=C)CCCC1(C)C)C=CC=C(/C)C=CC2C(=C)CCCC2(C)C UPYKUZBSLRQECL-UKMVMLAPSA-N 0.000 description 1
- JEVVKJMRZMXFBT-XWDZUXABSA-N Lycophyll Natural products OC/C(=C/CC/C(=C\C=C\C(=C/C=C/C(=C\C=C\C=C(/C=C/C=C(\C=C\C=C(/CC/C=C(/CO)\C)\C)/C)\C)/C)\C)/C)/C JEVVKJMRZMXFBT-XWDZUXABSA-N 0.000 description 1
- 206010060862 Prostate cancer Diseases 0.000 description 1
- 208000000236 Prostatic Neoplasms Diseases 0.000 description 1
- 206010046555 Urinary retention Diseases 0.000 description 1
- 208000028938 Urination disease Diseases 0.000 description 1
- 208000002495 Uterine Neoplasms Diseases 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 239000011149 active material Substances 0.000 description 1
- 230000000879 anti-atherosclerotic effect Effects 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 230000003078 antioxidant effect Effects 0.000 description 1
- 235000006708 antioxidants Nutrition 0.000 description 1
- 208000011775 arteriosclerosis disease Diseases 0.000 description 1
- 230000036770 blood supply Effects 0.000 description 1
- 230000006931 brain damage Effects 0.000 description 1
- 231100000874 brain damage Toxicity 0.000 description 1
- 208000029028 brain injury Diseases 0.000 description 1
- 235000021466 carotenoid Nutrition 0.000 description 1
- 150000001747 carotenoids Chemical class 0.000 description 1
- 230000010261 cell growth Effects 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 210000003169 central nervous system Anatomy 0.000 description 1
- 230000002490 cerebral effect Effects 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 235000009508 confectionery Nutrition 0.000 description 1
- 230000008602 contraction Effects 0.000 description 1
- 239000002537 cosmetic Substances 0.000 description 1
- 230000002354 daily effect Effects 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 235000006694 eating habits Nutrition 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 201000005577 familial hyperlipidemia Diseases 0.000 description 1
- 229930003944 flavone Natural products 0.000 description 1
- 150000002213 flavones Chemical class 0.000 description 1
- 235000011949 flavones Nutrition 0.000 description 1
- 230000005714 functional activity Effects 0.000 description 1
- PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical compound [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 description 1
- 239000010931 gold Substances 0.000 description 1
- 229910052737 gold Inorganic materials 0.000 description 1
- 230000012010 growth Effects 0.000 description 1
- 208000021822 hypotensive Diseases 0.000 description 1
- 230000001077 hypotensive effect Effects 0.000 description 1
- 230000036737 immune function Effects 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 230000001976 improved effect Effects 0.000 description 1
- 238000009776 industrial production Methods 0.000 description 1
- 210000000936 intestine Anatomy 0.000 description 1
- 239000010977 jade Substances 0.000 description 1
- 230000009191 jumping Effects 0.000 description 1
- 210000002429 large intestine Anatomy 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 201000005202 lung cancer Diseases 0.000 description 1
- 208000020816 lung neoplasm Diseases 0.000 description 1
- OAIJSZIZWZSQBC-GYZMGTAESA-N lycopene Chemical compound CC(C)=CCC\C(C)=C\C=C\C(\C)=C\C=C\C(\C)=C\C=C\C=C(/C)\C=C\C=C(/C)\C=C\C=C(/C)CCC=C(C)C OAIJSZIZWZSQBC-GYZMGTAESA-N 0.000 description 1
- 229960004999 lycopene Drugs 0.000 description 1
- 235000012661 lycopene Nutrition 0.000 description 1
- 239000001751 lycopene Substances 0.000 description 1
- 206010025482 malaise Diseases 0.000 description 1
- 239000008204 material by function Substances 0.000 description 1
- 230000006993 memory improvement Effects 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- 230000027939 micturition Effects 0.000 description 1
- 235000013336 milk Nutrition 0.000 description 1
- 239000008267 milk Substances 0.000 description 1
- 210000004080 milk Anatomy 0.000 description 1
- 210000000653 nervous system Anatomy 0.000 description 1
- 230000000474 nursing effect Effects 0.000 description 1
- 235000016709 nutrition Nutrition 0.000 description 1
- 230000035764 nutrition Effects 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 244000045947 parasite Species 0.000 description 1
- 239000000902 placebo Substances 0.000 description 1
- 229940068196 placebo Drugs 0.000 description 1
- 235000018102 proteins Nutrition 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 238000010791 quenching Methods 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 230000002000 scavenging effect Effects 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 230000035922 thirst Effects 0.000 description 1
- 235000013619 trace mineral Nutrition 0.000 description 1
- 239000011573 trace mineral Substances 0.000 description 1
- ZCIHMQAPACOQHT-ZGMPDRQDSA-N trans-isorenieratene Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/c1c(C)ccc(C)c1C)C=CC=C(/C)C=Cc2c(C)ccc(C)c2C ZCIHMQAPACOQHT-ZGMPDRQDSA-N 0.000 description 1
- 210000002700 urine Anatomy 0.000 description 1
- 206010046766 uterine cancer Diseases 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
- 238000009941 weaving Methods 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/105—Plant extracts, their artificial duplicates or their derivatives
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Botany (AREA)
- Mycology (AREA)
- Health & Medical Sciences (AREA)
- Nutrition Science (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Food Science & Technology (AREA)
- Polymers & Plastics (AREA)
- Medicines Containing Plant Substances (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicinal Preparation (AREA)
Abstract
The invention discloses a soyasterol tablet with a health care function and a preparation method of the soyasterol tablet. The soyasterol tablet comprises the following materials in percent by weight: 35-45 percent of soyasterol acetate, 10-12 percent of a tomato extract, 5-8 percent of phosphatidylserine, 6-10 percent of rape pollen, 4-9 percent of a pumpkin seed extract, 15-20 percent of DHA (docosahexaenoic acid) microalgae powder, and 3-10 percent of ganoderma lucidum spore. The preparation method of the soyasterol tablet comprises the following steps: respectively weighing all the materials in ratio; fully mixing the materials to form a uniform powdery intermediate product; and sending a uniform mixture of all the materials to a feeding bin of a tabletting machine, and directly tabletting by the tabletting machine to form a tablet formed product. The soyasterol tablet is capable of reducing cholesterol, blood fat, and blood pressure, preventing disease of prostate, improving the memory, and resisting inflammation and preventing cancers after being taken for long time; the preparation method of the soyasterol tablet is simple, and the soyasterol tablet is convenient to take, and suitable for popularization of products, and large-scale industrialized production and application.
Description
Technical field
The invention belongs to technical field of health care food, relate to a kind of sojasterol ester tablet with health care and preparation method thereof.
Background technology
The economic develop rapidly of society, living standards of the people improve constantly, the intake of cholesterol increases day by day, sickness influences such as incident high fat of blood, hypertension and endanger the life of people and healthy, and the incidence of disease especially for this type of disease of the elderly is higher.In addition, along with the increase at age, the function of various organ declines gradually, and the probability suffering from senile dementia, cancer, various inflammation etc. increases greatly, and middle-aged men and old men people also easily suffers from the disease of prostate aspect.Therefore, the nutrition and health care of the elderly is extremely important.
Sojasterol acetic acid esters is the functional activity material of a kind of novel reduction serum cholesterol, prevention and cure of cardiovascular disease, and it is decomposed into sojasterol and acetic acid in human body.Except reduction cholesterol, control cardiovascular and cerebrovascular disease, sterol ester also has the physiologically actives such as anti-inflammatory anti-cancer, liver protecting, skin-protecting face nursing, in field extensive application such as medicine, cosmetics, food, printing, weavings.
Lycopene is the one of carotenoid, is a kind of very strong antioxidant, has the ability of extremely strong scavenging free radicals.There is remarkable result to preventing and treating prostate cancer, lung cancer, breast cancer, the cancer of the uterus etc., preventing cardiovascular and cerebrovascular disease in addition, improve immunity, delaying senility, regulate the effects such as cholesterol metabolic, having the title of plant gold, be described as the new lover of health products " 21 century ".
Phosphatidyl serine is the active material of cell membrane, is especially present in brain cell.Phosphatidyl serine has raising cerebral function, improves senile dementia; Increase brain blood supply, promote that brainfag recovers; Protection central nervous system, helps the effect of repairing brain damage.
Rape pollen contains the functional materials such as rich in protein, trace element, flavones, these materials act synergistically on body, regulate the several functions of body, there is antiatherosclerosis, reduce cholesterol, radioresistance, develop immunitypty, prevent and treat the multiple curative effects such as prostatic disorders, add food pumpkin seeds effect during taking better.
Pumpkin seeds taste is sweet, and property is put down, and enters spleen, stomach, large intestine channel; There is expelling parasite cough-relieving, and in quench the thirst, increasing postpartum milk secretion, effect such as treatment hyperplasia of prostate etc.
DHA is commonly called as docosapentaenoic acid, a kind of essential element being nervous system cell growth and maintaining, be brain and amphiblestroid important composition composition, there is the growth of enhancement brain cell, Therapeutic cancer, improve senile dementia, promote the multiple effects such as phosphatidyl serine absorption.
Lucidum spore powder can strengthen immune function, prevention and therapy tumour and cancer; Reduce cholesterol, avoid vascular sclerosis; Reduce blood pressure, the generation of angiocardiopathy preventing.Strengthen liver, spleen and functions of intestines and stomach, perfect Alimentary running.
Currently marketed health products beautiful jade Lang meets the eye on every side, of a great variety, but special actually rare for the health products of middle-aged men and old men people.
Summary of the invention
The object of the invention is to overcome the deficiency that the health products kind of middle-aged men and old men people is few, provide a kind of specially for the sojasterol ester tablet with plurality of health care functions of middle-aged men and old men people.
The object of the invention is to be achieved through the following technical solutions:
There is a sojasterol ester tablet for health care, mainly comprise following material by weight percentage: sojasterol acetic acid esters 35-45, tomato extract 10-12, phosphatidyl serine 5-8, rape pollen 6-10, pumkin seed P.E 4-9, DHA microalgae powder 15-20, lucidum spore powder 3-10.
The preparation method of above-mentioned tablet comprises following steps:
(1) following material is by weight percentage taken respectively: sojasterol acetic acid esters 35-45, tomato extract 10-12, phosphatidyl serine 5-8, rape pollen 6-10, pumkin seed P.E 4-9, DHA microalgae powder 15-20, lucidum spore powder 3-10;
(2) above-mentioned various material is fully mixed, form uniform Powdered middle product;
(3) uniform various mixture of substances is delivered in the feeding bin of tablet press machine, by tablet press machine direct tablet compressing, form tablet shaped article.
Various relevant raw material, through repeatedly studying, constantly testing, are allocated according to scientific matching, are obtained a kind of sojasterol ester tablet with health care by the present invention, and in trial production process, define simple, effective preparation method.Long-term edible this sterol ester sheet, can reduce cholesterol, reducing blood lipid, hypotensive, prevention prostatic disorders, Improving memory, anti-inflammatory anti-cancer; And the preparation method of this product is simple, taking convenience, be applicable to the popularization of product and large-scale industrial production application.
For the health-care effect of sojasterol ester sheet, carried out crowd's test, clinical testing, animal experiment, result shows this tablet successful.
Reduce the functional aspect of cholesterol, reducing blood lipid, carry out crowd's test.Select 120 routine hyperlipemia crowds, test group and control group is divided into by factor Stochastic Equilibriums such as blood lipid level, age, sex, diet, test group oral sojasterol ester sheet, every day 3 times, each 2 (0.6g/ sheet), control group does not take any intervening measure, do not change daily life and eating habit, continuous 30 days, get blood, separation of serum, detects serum total cholesterol (TC), triglyceride (TG), HDL-C (HDL-C) level.Before TC, TG when found that test group off-test and test and compare, difference all has conspicuousness, and the total effective rate of test group reducing blood lipid is 85.2%.
Clinical and experimental study is cooperated with hospital, select primary hypertension patient 60 example, 51 years old mean age, respectively take sojasterol ester sheet after 1 month (3g/ days) measure blood pressure, heart rate, recording ecg.Result of study shows, takes the blood pressure that sojasterol ester sheet can reduce primary hypertension patient.
The effect of Improving memory, selects 120 mouse, and every 40 is one group, respectively by Jumping test, step-through test and water maze test, observes feeding the mouse memory improvement situation of raising sojasterol ester sheet.Result shows that sojasterol ester sheet is improved effect to the passive avoidance response of animal and the Memory acquisition of spatial discrimination.
200 routine benign prostatauxe patients are divided into two groups at random, take sojasterol ester sheet for one group, each 2 (0.5g/ sheet), every day 3 times.Another group takes placebo, continuous 3 months, is evaluated effect by indexs such as urine flow, enuresis nocturna number of times, residual urine volume and prostate volumes.Found that, taking sojasterol ester sheet has and suppresses hypertrophy of the prostate, improves the effect of bladder contraction, is forced to, the symptom such as urination disorder improves significantly effect to frequent micturition, bladder.
Detailed description of the invention
Below in conjunction with embodiment, technical scheme of the present invention is further described; but do not limit to so; everyly technical solution of the present invention modified or equivalent to replace, and not departing from the spirit and scope of technical solution of the present invention, all should be encompassed in protection scope of the present invention.
Embodiment 1:
There is a sojasterol ester tablet for health care, mainly comprise following material by weight percentage: sojasterol acetic acid esters 40, tomato extract 10, phosphatidyl serine 5, rape pollen 8, pumkin seed P.E 8, DHA microalgae powder 20, lucidum spore powder 9.The preparation method of this tablet comprises following steps:
(1) following material is by weight percentage taken respectively: sojasterol acetic acid esters 40, tomato extract 10, phosphatidyl serine 5, rape pollen 8, pumkin seed P.E 8, DHA microalgae powder 20, lucidum spore powder 9;
(2) above-mentioned various material is fully mixed, form uniform Powdered middle product;
(3) uniform various mixture of substances is delivered in the feeding bin of tablet press machine, by tablet press machine direct tablet compressing, form tablet shaped article.
Embodiment 2:
There is a sojasterol ester tablet for health care, mainly comprise following material by weight percentage: sojasterol acetic acid esters 45, tomato extract 12, phosphatidyl serine 5, rape pollen 6, pumkin seed P.E 4, DHA microalgae powder 20, lucidum spore powder 8.The preparation method of this tablet comprises following steps:
(1) following material is by weight percentage taken respectively: sojasterol acetic acid esters 45, tomato extract 12, phosphatidyl serine 5, rape pollen 6, pumkin seed P.E 4, DHA microalgae powder 20, lucidum spore powder 8;
(2) above-mentioned various material is fully mixed, form uniform Powdered middle product;
(3) uniform various mixture of substances is delivered in the feeding bin of tablet press machine, by tablet press machine direct tablet compressing, form tablet shaped article.
Embodiment 3:
There is a sojasterol ester tablet for health care, mainly comprise following material by weight percentage: sojasterol acetic acid esters 38, tomato extract 11, phosphatidyl serine 8, rape pollen 10, pumkin seed P.E 7, DHA microalgae powder 16, lucidum spore powder 10.The preparation method of this tablet comprises following steps:
(1) following material is by weight percentage taken respectively: sojasterol acetic acid esters 38, tomato extract 11, phosphatidyl serine 8, rape pollen 10, pumkin seed P.E 7, DHA microalgae powder 16, lucidum spore powder 10;
(2) above-mentioned various material is fully mixed, form uniform Powdered middle product;
(3) uniform various mixture of substances is delivered in the feeding bin of tablet press machine, by tablet press machine direct tablet compressing, form tablet shaped article.
Embodiment 4:
There is a sojasterol ester tablet for health care, mainly comprise following material by weight percentage: sojasterol acetic acid esters 43, tomato extract 12, phosphatidyl serine 7, rape pollen 9, pumkin seed P.E 6, DHA microalgae powder 18, lucidum spore powder 5.The preparation method of this tablet comprises following steps:
(1) following material is by weight percentage taken respectively: sojasterol acetic acid esters 43, tomato extract 12, phosphatidyl serine 7, rape pollen 9, pumkin seed P.E 6, DHA microalgae powder 18, lucidum spore powder 5;
(2) above-mentioned various material is fully mixed, form uniform Powdered middle product;
(3) uniform various mixture of substances is delivered in the feeding bin of tablet press machine, by tablet press machine direct tablet compressing, form tablet shaped article.
Claims (6)
1. there is a sojasterol ester tablet for health care, it is characterized in that described tablet is made up of following material by weight percentage: sojasterol acetic acid esters 35-45, tomato extract 10-12, phosphatidyl serine 5-8, rape pollen 6-10, pumkin seed P.E 4-9, DHA microalgae powder 15-20, lucidum spore powder 3-10.
2. the sojasterol ester tablet with health care according to claim 1, is characterized in that described tablet is made up of following material by weight percentage: sojasterol acetic acid esters 40, tomato extract 10, phosphatidyl serine 5, rape pollen 8, pumkin seed P.E 8, DHA microalgae powder 20, lucidum spore powder 9.
3. the sojasterol ester tablet with health care according to claim 1, is characterized in that described tablet is made up of following material by weight percentage: sojasterol acetic acid esters 45, tomato extract 12, phosphatidyl serine 5, rape pollen 6, pumkin seed P.E 4, DHA microalgae powder 20, lucidum spore powder 8.
4. the sojasterol ester tablet with health care according to claim 1, is characterized in that described tablet is made up of following material by weight percentage: sojasterol acetic acid esters 38, tomato extract 11, phosphatidyl serine 8, rape pollen 10, pumkin seed P.E 7, DHA microalgae powder 16, lucidum spore powder 10.
5. the sojasterol ester tablet with health care according to claim 1, is characterized in that described tablet is made up of following material by weight percentage: sojasterol acetic acid esters 43, tomato extract 12, phosphatidyl serine 7, rape pollen 9, pumkin seed P.E 6, DHA microalgae powder 18, lucidum spore powder 5.
6. the preparation method with the sojasterol ester tablet of health care described in the arbitrary claim of claim 1-5, is characterized in that described method step is as follows:
(1) various material is taken according to the percentage by weight described in the arbitrary claim of claim 1-5;
(2) above-mentioned various material is fully mixed, form uniform Powdered middle product;
(3) uniform various mixture of substances is delivered in the feeding bin of tablet press machine, by tablet press machine direct tablet compressing, form tablet shaped article.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201410147169.XA CN103876157B (en) | 2014-04-14 | 2014-04-14 | Soyasterol tablet with health care function and preparation method of soyasterol tablet |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201410147169.XA CN103876157B (en) | 2014-04-14 | 2014-04-14 | Soyasterol tablet with health care function and preparation method of soyasterol tablet |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN103876157A CN103876157A (en) | 2014-06-25 |
| CN103876157B true CN103876157B (en) | 2015-05-20 |
Family
ID=50945541
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201410147169.XA Expired - Fee Related CN103876157B (en) | 2014-04-14 | 2014-04-14 | Soyasterol tablet with health care function and preparation method of soyasterol tablet |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN103876157B (en) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3311821A1 (en) * | 2016-10-19 | 2018-04-25 | Nutrilinea S.r.l. | The use of phosphatidylserine for the prevention and treatment of prostate disorders, and the corresponding pharmaceutical and nutraceutical compositions |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN106720847A (en) * | 2016-10-20 | 2017-05-31 | 恩施硒德生物工程有限公司 | A kind of method that technique of direct powder compression prepares pressed candy |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101869592A (en) * | 2009-04-27 | 2010-10-27 | 北京百花蜂产品科技发展有限公司 | Formula and preparation method of pollen product |
| CN102018823A (en) * | 2009-09-17 | 2011-04-20 | 上海泰佳生物科技有限公司 | Composite preparation containing phospholipid, alpha-linolenic acid, gamma-linolenic acid and tomato extract |
| CN101879154A (en) * | 2010-02-23 | 2010-11-10 | 江苏格林生物科技有限公司 | Prostate repairing medicament formed by matching alpha-ricinoleic acid ethyl ester with lycopene |
| CN102366103B (en) * | 2011-10-29 | 2012-12-05 | 山西振东五和健康食品股份有限公司 | Food applicable to maintaining functions of middle-aged and old men |
| CN102895319A (en) * | 2012-11-12 | 2013-01-30 | 孟令刚 | Composition containing desert cistanche, cynomorium or medlar, pumpkin seeds and pollen |
| CN103054025A (en) * | 2013-01-04 | 2013-04-24 | 浙江大学 | Health-care food composition for preventing and treating prostate disease |
| CN103141845B (en) * | 2013-03-22 | 2014-11-05 | 山东三星玉米产业科技有限公司 | Soft phytosterol capsule and method for preparing same |
| CN103315299B (en) * | 2013-07-08 | 2014-11-19 | 北京东方红航天生物技术股份有限公司 | Health-care food with function of enhancing immunity and memory |
-
2014
- 2014-04-14 CN CN201410147169.XA patent/CN103876157B/en not_active Expired - Fee Related
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3311821A1 (en) * | 2016-10-19 | 2018-04-25 | Nutrilinea S.r.l. | The use of phosphatidylserine for the prevention and treatment of prostate disorders, and the corresponding pharmaceutical and nutraceutical compositions |
Also Published As
| Publication number | Publication date |
|---|---|
| CN103876157A (en) | 2014-06-25 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN104126808B (en) | A kind of slimming health food and preparation method thereof | |
| CN102302211B (en) | Health-care beverage | |
| CN104415061B (en) | Edible composition and its production and use | |
| CN106343567A (en) | Noni oral liquid and preparing method thereof | |
| EP2891496B1 (en) | PHARMACEUTICAL COMPOSITION CONTAINING COMPLEX EXTRACT OF CRATAEGI FRUCTUS and CITRI PERICARPIUM AS AN ACTIVE INGREDIENT FOR TREATING OR PREVENTING OBESITY OR LIPID-RELATED METABOLIC DISEASES | |
| CN103285145A (en) | Pure traditional Chinese medicine preparation for prompting rapid growth of pigs as well as preparation method and application method thereof | |
| CN103876157B (en) | Soyasterol tablet with health care function and preparation method of soyasterol tablet | |
| CN103142916A (en) | Medicament for preventing and treating senile dementia and preparation method thereof | |
| CN103349738A (en) | Traditional Chinese medicinal formula convenient for oral administration and external application of females | |
| CN103340919B (en) | Lucid ganoderma refined powder compound soft capsule and preparation method thereof | |
| CN105733880A (en) | Composite hazelnut wine brewed from hazelnut meal | |
| CN104256618A (en) | Food, health care product or medicine composition with blood sugar reduction function | |
| CN114831312B (en) | Traditional Chinese medicine composition composed of ganoderma lucidum polysaccharide and cicada fungus polysaccharide and application thereof | |
| CN112089783B (en) | Application of traditional Chinese medicine composition in preparation of medicine for preventing or/and treating obesity | |
| CN102698185A (en) | Traditional Tibetan medicine for treating hyperlipidemia and preparation method thereof | |
| CN106307502A (en) | Diet for treating acnes and improving skin textures | |
| CN104666460A (en) | Composition having efficacy of dispelling acnes as well as application and preparation of composition | |
| CN104522230A (en) | Instant cercis chinensis granules for promoting digestion | |
| CN103520408A (en) | Health care product tonifying brain and kidney and preparation method thereof | |
| CN103966063B (en) | Rose odorata Sweet var. gigantean (Coll.et Hemsl.) Rehd.et Wils fruit wine and preparation method thereof | |
| CN102631493B (en) | Health care composition | |
| CN102631389A (en) | Traditional Chinese medicine composition capable of improving immunity and resisting fatigue | |
| CN102631393B (en) | Health care composition | |
| CN102631487A (en) | Traditional Chinese medicine composition capable of improving immunity and resisting fatigue | |
| CN102511785A (en) | Composition with weight increasing function |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20150520 |
|
| CF01 | Termination of patent right due to non-payment of annual fee |